1Lee DP, Herity NA, Hiatt BL, et al. Adjunctive platelet glycoprction IIb/III a receptor inhibition with tirofihan before primary angioplasty improves angiographic outcome: results of the Tirofiban Give in the Emergency Room before Primary Angioplasty ( TIGER PA) pilot trial [J]. Circulation, 2003,107 (11):1497-1501.
2Kunichika H, Ben-Yehuda O, Lafitte S, et al. Effects of glycopretion IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast eehoeardiography study [ J]. J Am Coll Cardiol, 2004,43 ( 2 ) : 284- 286.
3Lavi S,Gruberg L,Kapeliovich M, et al. The impact of GP IIb/ IIIa inhibition druging primary percutaneous coronary intervention in acute myocardial infarction patients[J]. J Invasive Cardiol,2005,17(6) :300-301.
6Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percotancous Coronary Interventions of the European Society of Cardiology[J]. Eur Heart J ,2005,26(8):804-847.
3Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein Ⅱ b/Ⅲ a blockade with primary PTCA Organization and Randomized Trial ( RAPPORT ). Circulation, 1998,98 : 734-741.
4Montalescot G, Barragan P, Wittenberg O, et al. For the ADMIRAL Investigators. Platelet glycoprotein Ⅱ b/Ⅲ a inhibition with coronary stenting for acute myocardial infarction. N Eng J Med, 2001, 344:1895-1903.
5Stone GW, Grines CL, Cox DA, et al. Comparision of angioplasty with stenting, with or without abciximab, in acuete myocardial infarction. N Eng J Med, 2002, 346 : 957-966.
6Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein Ⅱ b/Ⅲ a receptor blockade on recovery flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infction. Circulation, 1998, 98 : 2695-2701.
7Petronioa AS, Rovai D, Musumeci G, et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Euro Heart Journal, 2003, 24: 67-76.
8The RESTORE Investigators. Effects of platelet glycoprotein Ⅱ b/Ⅲ a blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997, 96: 1445-1453.
9Lincoff AM. Trial of platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonists during percutaneous coronary revascularization. Am J Cardiol, 1998, 82:36-42.
10Danzi GB, Sesana M, Capuano C, et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol, 2004, 94:35-39.
